As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.
14 Analysts have issued a Ceribell forecast:
14 Analysts have issued a Ceribell forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 83 83 |
-
|
|
| Gross Profit | 73 73 |
-
|
|
| EBITDA | -55 -55 |
-
|
|
| EBIT (Operating Income) EBIT | -57 -57 |
-
|
|
| Net Profit | -52 -52 |
-
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ceribell, Inc. is a commercial-stage medical technology company, which focuses on transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point-of-Care EEG, which enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies, Clarity, an AI algorithm that interprets EEG in real-time, providing bedside alerts and continuous monitoring for status epilepticus, and EEG Portal, which makes it easy to remotely review EEG in real-time with pre-annotated EEG insights. The company was founded by Xing Juan Chao, Josef Parvizi, and Chris Chafe on August 29, 2014 and is headquartered in Sunnyvale, CA.
| Head office | United States |
| CEO | Xing Chao |
| Website | ceribell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


